Pancreatic ductal adenocarcinoma (PDAC) has long been dominated by one oncogenic force: KRAS. Because KRAS signaling drives much of the malignant phenotype, it can be difficult to distinguish which molecular pathways are truly fundamental to pancreatic tumor biology and which are merely downstream consequences of KRAS activation.

We therefore turned our attention to pancreatic acinar cell carcinoma (ACC), a rare pancreatic malignancy that develops largely independent of canonical KRAS-driven oncogenesis. Rather than viewing ACC as an orphan disease, we considered it a unique biological window through which hidden dependencies of pancreatic cancer might be exposed.

ACC functions as a natural experiment in pancreatic tumorigenesis. By removing the overwhelming influence of KRAS signaling, ACC may reveal molecular programs that are otherwise masked in conventional pancreatic cancer.

Our findings suggest that molecular stratification of pancreatic neoplasms based on RNA methylation states may complement existing genomic classifications.

RNA methylation-associated biomarkers could help identify patients most likely to benefit from emerging epitranscriptomic therapies.

Beyond ACC itself, this framework may enable a new generation of biomarker-guided therapeutic strategies across pancreatic diseases.

Rare cancers are often viewed as exceptions. Yet sometimes exceptions reveal the rules. By studying a pancreatic tumor that evolved outside the shadow of KRAS, we uncovered an unexpected dependency on RNA methylation. Whether this vulnerability extends to broader pancreatic disease remains an open question—but one that we are excited to pursue.

 METTL3 is not merely a therapeutic target in ACC; ACC is a biological lens through which previously hidden epitranscriptomic dependencies of pancreatic disease can be observed.